06 / INTAKE · 12 WEEKS
Observation in three phases from 2010 to 2026. Again and again, people were seen eating again, walking, sleeping, speaking and returning to daily life.
In plain words
Since 2010 I have applied GRBM to more than 600 people — from fetuses to the elderly, of many nationalities and conditions — following them for up to 15 years. These records are not approved efficacy but clinical signals. And those signals were very strong.
Seriously ill patients were seen again and again eating, walking, sleeping and speaking again, returning to daily life, and regaining family and social life. It was not simple symptom relief but a functional transformation of life.
What is needed now is not to prove the technology anew, but to translate the strong signals already observed into the global language of clinical science and an industrial model.
Early GRBM as "bio-kimchi," focused on a few: terminally ill patients, neurodevelopmental issues, absorption problems after gastrectomy — strong functional recovery in all participants, some sustained for over 15 years.
Mid-stage GRBM as "bio-smoothies," expanded to many cancers, viral diseases, neurodegenerative and neurodevelopmental disorders and cerebrovascular disease — strong responses in about 93.4%.
"GRBM metabolome + bio-smoothie + bio-kimchi," personalized: autoimmune, metastatic cancer, metabolic and complex diseases — strong functional recovery in all participants, with predictable recovery paths.
| Area | Observed change |
|---|---|
| Autoimmune · severe Crohn's disease | Bowel rest and detox → mucosal regeneration (from week 4) → structural stability (from week 7); complete remission and return to daily life by weeks 8–12 |
| Autoimmune · severe psoriasis | Marked reduction of erythema, no new lesions, long-term stability |
| Infertility | Natural pregnancy after repeated assisted-reproduction failures — pregnancy in all five cases applying the metabolic-alignment hypothesis |
| Fetal growth restriction | Growth recovery and birth after concern about poor growth in the 8th month of pregnancy |
| Breast cancer | Staged recovery and return to daily and family life |
| Moyamoya disease | Stepwise recovery from long-term reduced consciousness to expression and daily function |
| Shoulder calcification | Changes in density and outline of calcific shadows after one week, with fragmentation and reduction |
| Metastatic malignant osteosarcoma | Before-and-after imaging records of systemic metastatic findings |
| Alzheimer's · cerebrovascular | Before-and-after records of PET-CT (β-amyloid) and carotid/brain MRI |
The biggest limit of this research was not the technology's potential but the lack of capital and infrastructure to turn it into institutional clinical data. So most of it proceeded as volunteer-based internal observation. Still, before-and-after imaging, progress records and recovery reports remain, forming a basis for formal clinical design.
| Transition | Meaning |
|---|---|
| An industrial-ecosystem model | Turn about 600 observations into an industry linking raw materials, manufacturing, formulation, clinical work, medical institutions, data, regulation and licensing |
| Formal clinical trials by disease | Build protocols for cancer, autoimmune, neurodegenerative and metabolic diseases |
| High-value formulations | Develop injectables, high-absorption metabolomes and disease-specific formulations |
| Global clinical development & licensing | Pursue clinical development to FDA/EMA standards and out-licensing opportunities |
The question that matters to an investor is this: "Has this technology actually produced cases that changed people's lives?" GRBM's observation records give a clear answer.
Wooyoung Nam · developer of GRBM
This material is not the result of formal clinical trials claiming definitive therapeutic effect but the developer's (Wooyoung Nam's) volunteer-based internal observation records. Original materials can be reviewed during on-site due diligence in Uljin after an NDA.
PARTNERSHIP · INVESTMENT
After signing an NDA you can review the materials, then verify the original records and the process in person during on-site due diligence in Uljin, Gyeongsangbuk-do, Korea.
